Bora Pharmaceuticals partners with Accord BioPharma to boost UDENYCA production in the US

Bora Pharmaceuticals Co., Ltd. has entered into a strategic partnership with Accord BioPharma to manufacture pre-filled syringes of UDENYCA (pegfilgrastim-cbqv), a key biosimilar used to support immune system recovery in cancer patients undergoing chemotherapy. The collaboration underscores a shared commitment to bolstering domestic biopharmaceutical manufacturing and ensuring a stable, high-quality supply of critical oncology treatments in the United States.

Production will be based at Bora’s advanced Baltimore facility, which features the cutting-edge Groninger FlexPro 50 Isolator Line for vials and pre-filled syringes. The technology enables efficient, sterile, and flexible aseptic fill-finish operations, allowing Bora to meet Accord BioPharma’s growing demand for scalable production. The partnership also enhances the availability of UDENYCA, a treatment designed to reduce infection risks in patients with weakened immune systems due to chemotherapy.

David Fidler, Vice President and General Manager of Bora Pharmaceuticals Baltimore, said, “We’re excited to combine Bora’s manufacturing expertise with Accord’s vision to increase production capacity and expand domestic manufacturing. Our technical team’s experience in aseptic operations will play a key role in delivering reliable, high-quality output.”

Bora brings extensive contract development and manufacturing (CDMO) expertise, spanning early development, scale-up, process optimisation, and full commercial production. Its partnership with Accord reflects a broader trend of onshoring pharmaceutical production to strengthen supply chain resilience and reduce dependence on overseas facilities.

As demand for biologics and injectable therapies continues to rise, collaborations like this demonstrate the industry’s pivot towards localised, technology-driven solutions that prioritise patient access, quality, and speed to market.

Discover how this partnership is reshaping U.S. biomanufacturing and driving innovation in cancer care, explore the complete article today.